Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
Healthcare
$0.80 -4.09%
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
52W Low $0.91High $3.82
Volume 2.50M
Average 0.30M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$51.21M
FY 2025 · Annual
Investing Cash Flow
$9.82M
FY 2025 · Annual
Financing Cash Flow
$1.09M
FY 2025 · Annual
+381.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (204.94M) | (116.12M) | (59.38M) | (15.63M) | (55.48M) |
| Depreciation & Amortization | 640.98K | 1.01M | 988K | 660K | 704K |
| Deferred Income Tax | 106.37M | 3.37M | 0 | 0 | 0 |
| Stock-Based Compensation | 1.41M | 1.01M | 3.26M | 6.73M | 3.73M |
| Change in Working Capital | 3.27M | 7.16M | 9.49M | (15.49M) | 580K |
| Accounts Receivables | (2.53K) | 3.37K | 1.04M | (789K) | 776K |
| Inventory | 2.53K | (3.37K) | 0 | 0 | 0 |
| Accounts Payables | 8.89M | 375.66K | (4.28M) | (1.87M) | 1.62M |
| Other Working Capital | (5.62M) | 6.78M | 12.72M | (12.83M) | (1.82M) |
| Other Non-Cash Items | 6.91K | (1.35M) | (2.28M) | 118K | (736K) |
| Operating Cash Flow | (85.57M) | (99.27M) | (47.93M) | (23.61M) | (51.21M) |
| Capital Expenditures | (7.46M) | (4.28M) | (294K) | (750K) | (434K) |
| Acquisitions (Net) | 47.74K | 79.16K | 2.94M | 0 | 0 |
| Purchases of Investments | (17.98M) | (113.7M) | (32.6M) | (15.45M) | (30.47M) |
| Sales of Investments | 20.1M | 34.54M | 105.19M | 12.63M | 39.95M |
| Other Investing Activities | (47.74K) | (79.16K) | (84K) | 123K | 775K |
| Investing Cash Flow | (5.34M) | (83.44M) | 75.16M | (3.45M) | 9.82M |
| Debt Repayment | (126K) | (222K) | (290K) | 0 | 0 |
| Common Stock Issued | 219.99M | 18K | 44K | 227K | 1.09M |
| Common Stock Repurchased | (566K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | 119K | 0 | 0 | 0 |
| Financing Cash Flow | 206.66M | (91.29K) | (246K) | 227K | 1.09M |
| Effect of Forex Changes | (6.34M) | 13.87M | 18K | (595K) | 408K |
| Net Change in Cash | 109.42M | (168.93M) | 27M | (27.43M) | (39.89M) |
| Free Cash Flow | (93.03M) | (103.55M) | (48.22M) | (24.36M) | (51.64M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$55.5M
+ D&A$704.0K
+ Stock-Based Comp$3.7M
+ Deferred Tax$0
+ Working Capital$580.0K
- Other Non-Cash-$736.0K
= Operating Cash Flow-$51.2M
- Capex-$434.0K
= Free Cash Flow-$51.6M
Analysis
FY2025 free cash flow is -$51.6M. FCF conversion is 93.1% of net income. Operating cash flow was -$51.2M, with capex of -$434.0K. The largest bridge item is Stock-Based Comp at $3.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| 8-K | Current report | Sep 15, 2026 |
Does CNTB generate free cash flow?
Connect Biopharma Holdings Limited (CNTB) generated -$51.64M of free cash flow in fiscal 2025.
How much operating cash flow does CNTB produce?
Operating cash flow was -$51.21M, before capital expenditures of $434,000.00.
Continue the stock analysis
Jump to another research area for this company.